Mahwah, New Jersey, August 19, 2025 – Glenmark Pharmaceuticals Inc., USA is set to introduce Micafungin for Injection USP (50 mg/vial and 100 mg/vial single-dose vials) in September 2025, after receiving U.S. FDA approval. The product is bioequivalent and therapeutically equivalent to Astellas Pharma’s Mycamine®, expanding Glenmark’s institutional injectable portfolio.
Business Significance
The U.S. antifungal injectables market continues to present a sizeable opportunity. According to IQVIA®, sales of Mycamine® (brand and therapeutic equivalents) totaled $60.7 million in the 12 months ending June 2025. With the entry of Glenmark’s Micafungin, hospitals and healthcare systems could see a lower-cost alternative in a market where cost pressures and drug shortages remain persistent challenges. For Glenmark, this launch strengthens its positioning in the institutional generics space in North America, building on its strategy to diversify beyond oral solids into complex injectables. As Marc Kikuchi, President & Business Head, North America, highlighted: “We are excited to announce the launch … growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring quality and affordable alternatives to market for patients in need.” This move also signals Glenmark’s continued intent to compete in specialty and hospital-focused markets, areas traditionally dominated by larger players.
Clinical Significance
Micafungin belongs to the echinocandin class of antifungal agents, which are often the first-line therapy for invasive candidiasis and candidemia—serious, life-threatening fungal infections, especially in immunocompromised and hospitalized patients. By ensuring bioequivalence to Mycamine®, Glenmark’s formulation offers clinicians confidence in safety, efficacy, and therapeutic outcomes. Its availability in two vial strengths (50 mg and 100 mg) provides flexibility in dosing for both adult and pediatric patients. The clinical importance lies in addressing the growing incidence of antifungal resistance, where access to reliable and affordable treatment options becomes critical. Hospitals frequently face supply chain disruptions for injectable antifungals, and Glenmark’s entry could improve treatment continuity.
Regulatory Significance
Advertisement
The U.S. FDA approval of Glenmark’s Micafungin reflects the regulator’s continued support for generic competition in complex injectable categories. These approvals are subject to rigorous review for bioequivalence, sterility, and stability, ensuring that generics meet the same stringent standards as branded products. This launch underscores Glenmark’s capability to navigate high-bar regulatory pathways and align with FDA’s broader policy goal of increasing the availability of affordable medicines in essential therapeutic areas. It also adds to Glenmark’s growing reputation as a research-led, globally compliant company, with a track record of approvals in both oral and injectable categories.
About Glenmark:
Glenmark Pharmaceuticals Ltd. is a research-driven global pharmaceutical company operating in over 80 countries with 11 world-class manufacturing facilities across four continents. With a strong focus on respiratory, dermatology, and oncology treatments, Glenmark ranks among the top global generics and biosimilars companies. The company’s sustainability goals have been validated by the Science Based Target initiative (SBTi), and through multiple CSR programs, Glenmark has positively impacted over 3 million lives in the last decade.
Source: Glenmark Pharmaceuticals
